6-K 1 m12766ore6vk.txt FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April, 2004 Commission File Number: 000-50393 NEUROCHEM INC. 7220 Frederick-Banting, Suite 100 Saint-Laurent, Quebec H4S 2A1 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [ ] No [X] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [ ] No [X] Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934. Yes [ ] No [X] If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): SIGNATURES: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NEUROCHEM INC. April 28, 2004 By: /s/ David Skinner ------------------------------------ David Skinner Director, Legal Affairs, General Counsel and Corporate Secretary NEUROCHEM INC. 7220 Frederick-Banting, Suite 100 [LOGO (NEUROCHEM)] Saint-Laurent, Qc H4S 2A1 Canada ________________________________________________________________________________ NEUROCHEM TO PRESENT AT CIBC WORLD MARKETS ANNUAL BIOTECHNOLOGY AND SPECIALTY PHARMACEUTICALS CONFERENCE MONTREAL, CANADA, APRIL 27, 2004 - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced today that on Wednesday April 28, 2004, Dr. Francesco Bellini, Chairman and CEO, will present Neurochem's overall strategy and progress to date at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference to be held in New York City. The presentation will take place at 2:45 P.M. EDT. The corporate presentation will be available on the Company's website at http://www.neurochem.com/Investor.htm#Presentation. An audio webcast of Neurochem's presentation can also be accessed at http://www.veracast.com/webcasts/cibcwm/biotech04/01212215.cfm. This webcast will be available for 30 days through to May 28, 2004. ABOUT NEUROCHEM Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. Fibrillex(TM), designated an orphan drug and a Fast Track Product candidate, is in a Phase II/III clinical trial for AA amyloidosis. Alzhemed(TM) and Cerebril(TM) have completed a Phase II clinical trial for Alzheimer's Disease and for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy respectively. For additional information on Neurochem, please visit our website at: www.neurochem.com. Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. FOR FURTHER INFORMATION, PLEASE CONTACT: Lise Hebert, Ph.D. Vice President, Corporate Communications lhebert@neurochem.com --------------------- Tel: (514) 337-4646 Fax: (514) 337-5339